Market Overview

DFINE Announces Launch of StabiliT® ERX, The Latest Advancement in Family of Energy-Responsive, Ultra-High Viscosity Bone Cements

SAN JOSE, Calif.--(BUSINESS WIRE)--

DFINE, Inc., the developer of minimally invasive radiofrequency (RF) targeted therapies for the treatment of vertebral pathologies, today announced the launch of its StabiliT® ERX Bone Cement for use with the company's StabiliT® Vertebral Augmentation System. The System harnesses the power of RadioFrequency Targeted Vertebral Augmentation™ (RF-TVA) to relieve pain and repair vertebral compression fractures (VCFs) resulting from instability due to osteoporosis or cancer.

StabiliT ERX is the next-generation addition to DFINE's portfolio of energy-responsive, ultra-high viscosity cements. With five times greater viscosity than other PMMA bone cements, and about two times the viscosity of DFINE's StabiliT ER2 cement, StabiliT ERX is ideal for the treatment of complex osteoporotic and oncologic fractures – including cases with large voids, osteolytic or vascular fractures.

“Patients with complex fractures, such as non-healed vertebra plana fractures, can be very difficult to treat because there may be a limited amount of bone with which to work to stabilize the vertebra. With its significantly higher viscosity, StabiliT ERX affords a more targeted and controlled delivery - potentially reducing the likelihood of extravasation while still allowing for easy delivery into the vertebral body,” said Nick Yee, M.D., Interventional Radiologist, Radiology Imaging Associates, Englewood, CO.

In addition to higher viscosity, the advantages of StabiliT ERX Bone Cement include:

  • Extended working time - providing physicians with procedural flexibility.
  • Greater radiopacity during cement delivery, improving visibility under fluoroscopy.

“The combination of RF energy, targeted navigation and controlled delivery of ultra-high viscosity cement enables physicians to provide fracture reduction with minimal damage to native bone and greater precision in cement delivery,” said Kevin Mosher, Chief Executive Officer of DFINE. “Now with the introduction of StabiliT ERX as the latest advancement in our family of energy-responsive cements, physicians have greater choice in tailoring their treatments to each particular patient situation when using the StabiliT System.”

About DFINE, Inc.

DFINE is dedicated to relieving pain and improving the quality of life for patients suffering from vertebral pathologies through innovative, minimally invasive, targeted therapies. The company's devices are built on an extensible radiofrequency (RF) platform that currently covers two procedural applications: 1. The treatment of vertebral compression fractures (VCFs) with the StabiliT® Vertebral Augmentation System, and 2. The palliative treatment of metastatic vertebral body lesions with the STAR™ Tumor Ablation System. Both systems represent generational advancements in the minimally invasive treatment of vertebral pathologies. DFINE is based in San Jose, Calif. and is a privately held company. Stay connected with DFINE via Facebook or Twitter (@DFINEinc) or call 1.866.963.3463.

For DFINE, Inc.
Susan Benton Russell, 310-697-3488
susan@bentoncommunications.com

 

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters